Aug 13, 2025
Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in China
Aug 08, 2025
RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA
Jun 17, 2025
RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis
Jun 02, 2025
2025 ASCO Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer
May 27, 2025
RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China
May 12, 2025
Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS
Feb 14, 2025
ASCO GU RemeGen Announced Highly Encouraging Data from the Phase II Clinical Trial Evaluating Disitamab Vedotin plus Immunotherapy as Perioperative Regimen for Bladder Cancer
Oct 29, 2024
RemeGen Announces the Acceptance of the Marketing Application of Telitaccept for the Treatment of Myasthenia Gravis in China
Aug 06, 2024
First patient enrollment in the U.S. - A milestone for the global multi-center phase clinical trial of telitacicept for myasthenia gravis
Jun 05, 2024
RemeGen Showcases Research Results at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, Highlighting Its Prolific Innovation in Global Cancer Treatment
Jun 03, 2024
RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88
May 21, 2024
RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren's Syndrome
May 10, 2024
RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing
Apr 02, 2024
RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome
Mar 10, 2024
RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024
Feb 02, 2024
World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap
Jan 12, 2024
RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients